Research
Hormonal
The treatment landscape for glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is evolving.
Practitioners should stay updated on the evolving treatments for diabetes management.
StrongSupportsmedium confidence
we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward.
Why this rating
The claim is based on a review of recently published studies.
Source
The year in cardiovascular medicine 2021: diabetes and metabolic disorders
Francesco Cosentino et al. · European Heart Journal · 2021
reviewCited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →